We have prepared a slot for the CelltiX CSR Program for the first 50 people who want to try it. If you are interested in joining this program, please click on the button next to it.​

RESEARCH TEAM FROM
​CELL TISSUE TECHNOLOGY

COLLABORATION WITH RESEARCH UNIVERSITIES

In addition, many leading universities and research centres in Malaysia are actively involved in conducting research on the potential of bioactive factors for clinical use. Among them are:

If you have any questions about the CelltiX CSR Program, you can contact us at:

References

  1. Gupta, A., Kashte, S., Gupta, M., Rodriguez, H. C., Gautam, S. S., & Kadam, S. (2020). Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective. Human cell, 33(4), 907–918. https://doi.org/10.1007/s13577-020-00407-w. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418088/
  2. Gurunathan, S., Kang, M. H., & Kim, J. H. (2021). Diverse effects of exosomes on COVID-19: A perspective of progress from transmission to therapeutic developments. Frontiers in Immunology, 12. https://www.frontiersin.org/articles/10.3389/fimmu.2021.716407/full
  3. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England), 395(10223), 497–506. https://pubmed.ncbi.nlm.nih.gov/31986264/
  4. de la Rica, R., Borges, M., & Gonzalez-Freire, M. (2020). COVID-19: In the Eye of the Cytokine Storm. Frontiers in immunology, 11, 558898. https://doi.org/10.3389/fimmu.2020.558898. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541915/
  5. Khadke, S., Ahmed, N., Ahmed, N., Ratts, R., Raju, S., Gallogly, M., ... & Sohail, M. R. (2020). Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virology journal, 17(1), 1-18. https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01415-w#citeas
  6. Li, L., Huang, Q., Wang, D. C., Ingbar, D. H., & Wang, X. (2020). Acute lung injury in patients with COVID-19 infection. Clinical and translational medicine, 10(1), 20–27. https://doi.org/10.1002/ctm2.16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240840/
  7. Clinical Spectrum of SARS-CoV-2 Infection, NIH. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
  8. Spagnolo, P., Balestro, E., Aliberti, S., Cocconcelli, E., Biondini, D., Casa, G. D., Sverzellati, N., & Maher, T. M. (2020). Pulmonary fibrosis secondary to COVID-19: a call to arms?. The Lancet. Respiratory medicine, 8(8), 750–752. https://doi.org/10.1016/S2213-2600(20)30222-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228737/
  9. Wadman, M., Couzin-Frankel, J., Kaiser, J., & Matacic, C. (2020). A rampage through the body. https://www.science.org/doi/abs/10.1126/science.368.6489.356
  10. Zaim, S., Chong, J. H., Sankaranarayanan, V., & Harky, A. (2020). COVID-19 and Multiorgan Response. Current problems in cardiology, 45(8), 100618. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187881/
  11. Yu, B., Zhang, X., & Li, X. (2014). Exosomes derived from mesenchymal stem cells. International journal of molecular sciences, 15(3), 4142–4157. https://doi.org/10.3390/ijms15034142. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975389/
  12. Phinney, D. G., & Pittenger, M. F. (2017). Concise review: MSC‐derived exosomes for cell‐free therapy. Stem cells, 35(4), 851-858. https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/stem.2575
  13. Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., ... & Wan, E. Y. (2021). Post-acute COVID-19 syndrome. Nature medicine, 27(4), 601-615. https://www.nature.com/articles/s41591-021-01283-z#citeas
  14. Garis Panduan KKM Post-COVID-19. https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm/ANNEX_50_POST_COVID-19_MANAGEMENT_PROTOCOL_12JULY2021.pdf
  15. Jayaramayya, K., Mahalaxmi, I., Subramaniam, M. D., Raj, N., Dayem, A. A., Lim, K. M., Kim, S. J., An, J. Y., Lee, Y., Choi, Y., Raj, A., Cho, S. G., & Vellingiri, B. (2020). Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment. BMB reports, 53(8), 400–412. https://doi.org/10.5483/BMBRep.2020.53.8.121. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473478/
  16. Gurunathan, S., Kang, M. H., & Kim, J. H. (2021). Diverse effects of exosomes on COVID-19: A perspective of progress from transmission to therapeutic developments. Frontiers in Immunology, 12. https://www.frontiersin.org/articles/10.3389/fimmu.2021.716407/full
  17. Drew, D. A., Guo, C. G., Lee, K. A., Nguyen, L. H., Joshi, A. D., Lo, C. H., ... & Chan, A. T. (2021). Aspirin and NSAID use and the risk of COVID-19. medRxiv. https://covid-19.cochrane.org/studies/crs-13265944
  18. Gardin, C., Ferroni, L., Chachques, J. C., & Zavan, B. (2020). Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?. Journal of clinical medicine, 9(9), 2762. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565764/
  19. Bari, E., Ferrarotti, I., Saracino, L., Perteghella, S., Torre, M. L., Richeldi, L., & Corsico, A. G. (2021). Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?. Cells, 10(5), 1203. https://doi.org/10.3390/cells10051203. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155949/
  20. The Jerusalem Post. https://www.jpost.com/health-science/covid-90-percent-of-patients-treated-with-new-israeli-drug-discharged-in-5-days-67596
  21. Lee, J. H., Park, J., & Lee, J. W. (2019). Therapeutic use of mesenchymal stem cell-derived extracellular vesicles in acute lung injury. Transfusion, 59(S1), 876–883. https://doi.org/10.1111/trf.14838. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368889/
  22. Abdelgawad, M., Bakry, N. S., Farghali, A. A., Abdel-Latif, A., & Lotfy, A. (2021). Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects. Stem cell research & therapy, 12(1), 1-20. https://stemcellres.biomedcentral.com/articles/10.1186/s13287-021-02542-z#citeas
  23. Schulman, I. H., Balkan, W., & Hare, J. M. (2018). Mesenchymal stem cell therapy for aging frailty. Frontiers in nutrition, 5, 108. https://www.frontiersin.org/articles/10.3389/fnut.2018.00108/full
  24. Srinivasan, A., & Sundar, I. K. (2021). Recent updates on the role of extracellular vesicles in the pathogenesis of allergic asthma. Extracellular vesicles and circulating nucleic acids, 2, 127–147. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372030/
  25. Maremanda, K. P., Sundar, I. K., & Rahman, I. (2019). Protective role of mesenchymal stem cells and mesenchymal stem cell-derived exosomes in cigarette smoke-induced mitochondrial dysfunction in mice. Toxicology and applied pharmacology, 385, 114788. https://doi.org/10.1016/j.taap.2019.114788. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894395/
  26. Xu, B., Gan, C. X., Chen, S. S., Li, J. Q., Liu, M. Z., & Guo, G. H. (2020). BMSC-derived exosomes alleviate smoke inhalation lung injury through blockade of the HMGB1/NF-κB pathway. Life sciences, 257, 118042. https://doi.org/10.1016/j.lfs.2020.118042. https://pubmed.ncbi.nlm.nih.gov/32621926/
  27. Panagiotou, N., Neytchev, O., Selman, C., & Shiels, P. G. (2018). Extracellular Vesicles, Ageing, and Therapeutic Interventions. Cells, 7(8), 110. https://doi.org/10.3390/cells7080110. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115766/
  28. Clinical Trial NCT04491240. ​https://www.clinicaltrials.gov/ct2/show/results/NCT04491240
  29. Chu, M., Wang, H., Bian, L., Huang, J., Wu, D., Fei, F., ... & Xia, J. (2020). Nebulization Therapy for COVID-19 Pneumonia with Embryonic Mesenchymal Stem Cells-Derived Exosomes. https://europepmc.org/article/PPR/PPR233088
  30. Zambrano, G. M. T., Ahmed, Y. M., Carmenate, Y. V., & Elsadawy, M. E. (2021). Stem cell nebulization therapy for COVID-19 infection: radiological and clinical outcomes. Egyptian Journal of Radiology and Nuclear Medicine, 52(1), 1-11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079845/pdf/43055_2021_Article_492.pdf
  31. Alzahrani, F. A., Saadeldin, I. M., Ahmad, A., Kumar, D., Azhar, E. I., Siddiqui, A. J., ... & Jahan, S. (2020). The potential use of mesenchymal stem cells and their derived exosomes as immunomodulatory agents for COVID-19 patients. Stem Cells International, 2020. https://www.hindawi.com/journals/sci/2020/8835986/​

CELL TISSUE TECHNOLOGY SDN BHD
Malaysia's FIRST Tissue Engineering Firm
Sustainability Policy
Disclaimer
Terms of Use
Privacy Policy

Proudly powered by CTTSB
© 2010-2022 Cell Tissue Technology Sdn Bhd,
a Universiti Kebangsaan Malaysia spin-off Company.
All rights reserved.

MOST VALUABLE BRAND IN HEALTHCARE - TISSUE ENGINEERING & REGENERATIVE MEDICINE